Vigil Neuroscience (NASDAQ:VIGL) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a research note released on Wednesday, Benzinga reports. The brokerage currently has a $24.00 price objective on the stock.

Separately, JMP Securities reaffirmed a market outperform rating and set a $23.00 price target on shares of Vigil Neuroscience in a research report on Thursday, April 18th.

Vigil Neuroscience Price Performance

VIGL opened at $3.78 on Wednesday. The firm’s fifty day moving average price is $3.08 and its two-hundred day moving average price is $3.72. The company has a market capitalization of $142.07 million, a price-to-earnings ratio of -1.77 and a beta of 1.87. Vigil Neuroscience has a 1 year low of $2.50 and a 1 year high of $11.11.

Vigil Neuroscience (NASDAQ:VIGL) last released its quarterly earnings results on Tuesday, March 26th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.01). As a group, equities analysts anticipate that Vigil Neuroscience will post -2.56 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Vigil Neuroscience stock. Strs Ohio bought a new position in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 8,200 shares of the company’s stock, valued at approximately $27,000. 83.64% of the stock is owned by institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.